Navigation Links
Life Technologies Names Dr. Ora Hirsch Pescovitz to its Board of Directors
Date:4/29/2011

CARLSBAD, Calif., April 29, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that its shareholders have approved Dr. Ora Hirsch Pescovitz, Executive Vice President for Medical Affairs and Health System Chief Executive Officer at the University of Michigan, as a new member of its Board of Directors.

(Photo: http://photos.prnewswire.com/prnh/20110429/LA92180)

Dr. Pescovitz will be replacing Dr. W. Ann Reynolds Ph.D., who is retiring after serving on the board for six years.

"Dr. Pescovitz' considerable experience as a researcher, clinician and leader of one of the largest medical systems and academic universities in the world will be invaluable to Life Technologies as it develops its molecular medicine platform and brings its cutting edge technologies into the clinical environment," said Gregory T. Lucier, Chairman of the Board and CEO of Life Technologies. "We are exceptionally grateful to Dr. Reynolds for her years of service and the wisdom she brought to the organization as it went through transformative growth, and wish her well in her retirement."

Dr. Pescovitz is responsible for the leadership and management of the University of Michigan's Health System, which includes the U-M Hospitals and Health Centers, the U-M Medical School and its Faculty Group Practice, the clinical services of the U-M School of Nursing and the Michigan Health Corp., which enables the formation of partnerships outside the University. Dr. Pescovitz is responsible for oversight of $3 billion in revenue and a Medical School ranked 9th nationally in NIH funding, with more than $481 million in research funding.

Prior to taking the U-M post, Dr. Pescovitz had an extensive career serving as Executive Associate Dean for Research Affairs at Indiana University School of Medicine, President and CEO of Riley Hospital for Children in Indianapolis and Interim Vice President for Research Administration at Indiana University. Dr. Pescovitz is also a nationally recognized pediatric endocrinologist and researcher who has published 180 papers and books, and received numerous awards for her research and teaching.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition.  Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better.  Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics.  The company manufactures both molecular diagnostic and research use only products.  Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses.  For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.  Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Tim Ingersoll
760-918-3883
tim.ingersoll@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. RainDance Technologies Appoints Olex Vice President, System Development
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
5. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. Anthill Technologies Announces Agreement With Zafgen
9. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
10. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
11. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
(Date:2/16/2017)... February 16, 2017 Patient ... of innovative telemedicine application, new and leading edge ... experiencing a boom worldwide. The healthcare sector as ... technologies, services and new therapies for companies such ... RHT), Cellectar Biosciences, Inc. (NASDAQ: CLRB ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure ... was performed on a 55-year-old practicing female physician suffering from degenerative disc disease ...
(Date:2/16/2017)... , ... February 16, 2017 ... ... Molecular Research Inc. has further extended its industry leading Biochemistry Services specifically ... offers state-of-the-art cGMP techniques and methods for the biochemical and biosimilar ...
Breaking Biology Technology:
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
Breaking Biology News(10 mins):